Expression of melanocortin receptors in human prostate cancer cell lines: MC2R activation by ACTH increases prostate cancer cell proliferation

International Journal of Oncology

Volumn 41, Issue 4, 2012, Pages 1373-1380

  Hafiz, Saly ^a,b   Dennis, John C ^a   Schwartz, Dean ^a   Judd, Robert ^a   Tao, Ya Xiong ^a   Khazal, Kamel ^b   Akingbemi, Benson ^a   Mo, Xiu Lei ^a   Abdel Mageed, Asim B ^c   Morrison, Edward ^a   Mansour, Mahmoud ^a  

^a AUBURN UNIVERSITY   (United States)

^b TUSKEGEE UNIVERSITY   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenocorticotropic hormone; Androgen receptor; G protein coupledreceptors; Melanocortin receptor 2; Melanocortin receptors; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; CORTICOTROPIN; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 2 RECEPTOR; MELANOCORTIN 2 RECEPTOR ACCESSORY PROTEIN ALPHA; MELANOCORTIN 2 RECEPTOR ACCESSORY PROTEIN BETA; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 5 RECEPTOR; MESSENGER RNA; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; PROTEIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE MICROSCOPY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADRENOCORTICOTROPIC HORMONE; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOCYTE-STIMULATING HORMONES; PITUITARY GLAND, ANTERIOR; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84866485226     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1574     Document Type: Article

References (43)

1. Woolf SH: Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med 333: 1401-1405, 1995.
2. Oh WK, Kantoff PW: Management of hormone refractory prostate cancer: Current standards and future prospects. J Urol 160: 1220-1229, 1998.
3. Li TH, Zhao H, Peng Y, Beliakoff J, Brooks JD and Sun Z: A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res 35: 2767-2776, 2007.
4. Huggins C: Endocrine-induced regression of cancers. Cancer Res 27: 1925-1930, 1967.
5. Debes JD, Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351: 1488-1490, 2004.
6. Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45, 2001.
7. Nguyen MM and Wang Z: Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer. Minerva Urol Nefrol 60: 15-29, 2008.
8. Grossmann ME, Huang H, Tindall DJ: Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93: 1687-1697, 2001.
9. Craft N, Shostak Y, Carey M and Sawyers CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5: 280-285, 1999.
10. Linja MJ and Visakorpi T: Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 92: 255-264, 2004.
11. Vis AN and Schröder FH: Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int 104: 438-448, 2009.
12. Culig Z, Hobisch A, Cronauer MV, et al: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Eur Urol 27 (Suppl 2): 45-47, 1995.
13. Dorsam RT and Gutkind JS: G-protein-coupled receptors and cancer. Nat Rev Cancer 7: 79-94, 2007.
14. Daaka Y: G proteins in cancer: The prostate cancer paradigm. Sci STKE: re2, 2004.
15. Mendiratta P, Armstrong AJ and George DJ: Current standard and investigational approaches to the management of hormone-refractory prostate cancer. Rev Urol 9: S9-S19, 2007.
16. Raj GV, Barki-Harrington L, Kue PF and Daaka Y: Guanosine phosphate binding protein coupled receptors in prostate cancer: A review. J Urol 167: 1458-1463, 2002.
17. Xia C, Ma W, Wang F, Hua SB, Liu M: Identification of a prostate-specific G-protein coupled receptor in prostate cancer. Oncogene 13: 5903-5907, 2001.
18. Wang J, Weng J, Cai Y, Penland R, Liu M, Ittmann M: The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase. Prostate 1: 847-857, 2006.
19. Weng J, Wang J, Cai Y, et al: Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. Int J Cancer 113: 811-818, 2005.
20. Yowell CW and Daaka Y: G protein-coupled receptors provide survival signals in prostate cancer. Clin Prostate Cancer 1: 177-181, 2002.
21. Sun L, Luo J, Mackey LV, et al: Investigation of cancer cell lines for peptide receptor-targeted drug development. J Drug Target 19: 719-730, 2011.
22. Gutkind JS: Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors. Sci STKE: re1, 2000.
23. McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the Protooncogene bcl-2 in the Prostate and Its Association with Emergence of Androgen-independent Prostate Cancer. Cancer Res 52: 6940-6944, 1992.
24. Kasbohm EA, Guo R, Yowell CW, et al: Androgen receptor activation by G (s) signaling in prostate cancer cells. J Biol Chem 280: 11583-11589, 2005.
25. Merkle D and Hoffmann R: Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: Cross-talk with the androgen receptor. Cell Signal 23: 507-515, 2011.
26. Luscombe CJ, French ME, Liu S, et al: Prostate cancer risk: Associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br J Cancer 85: 1504-1509, 2001.
27. Wisse BE, Frayo RS, Schwartz MW and Cummings DE: Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 142: 3292-3301, 2001.
28. Chen W, Kelly MA, Opitz-Araya X, Thomas RE, Low MJ and Cone RD: Exocrine gland dysfunction in MC5-R-deficient mice: Evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 91: 789-798, 1997.
29. Roy S, Pinard S, Chouinard L and Gallo-Payet N: Adreno-corticotropin hormone (ACTH) effects on MAPK phosphorylation in human fasciculata cells and in embryonic kidney 293 cells expressing human melanocortin 2 receptor (MC2R) and MC2R accessory protein (MRAP)β. Mol Cell Endocrinol 336: 31-40, 2011.
30. Alwani RA, Neggers SJ, van der Klift M, et al: Cushing's syndrome due to ectopic ACTH production by (neuroendocrine) prostate carcinoma. Pituitary 12: 280-283, 2009.
31. Mansour M, Schwartz D, Judd R, et al: Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. Int J Oncol 38: 537-546, 2011.
32. Tao YX, Huang H, Wang ZQ, Yang F, Williams JN and Nikiforovich GV: Constitutive activity of neural melanocortin receptors. Methods Enzymol 484: 267-279, 2010.
33. Mansour M, White D, Wernette C, et al: Pancreatic neuronal melanocortin-4 receptor modulates serum insulin levels independent of leptin receptor. Endocrine 37: 220-230, 2010.
34. Marinissen MJ and Gutkind JS: G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 22: 368-376, 2001.
35. Labrie F, Belanger A, Dupont A, Luu-The V, Simard J and Labrie C: Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 16: 475-492, 1993.
36. Roy S, Rached M and Gallo-Payet N: Differential regulation of the human adrenocorticotropin receptor [melanocortin-2 receptor (MC2R)] by human MC2R accessory protein isoforms alpha and beta in isogenic human embryonic kidney 293 cells. Mol Endocrinol 21: 1656-1669, 2007.
37. Cone RD: Studies on the physiological functions of the melanocortin system. Endocr Rev 27: 736-749, 2006.
38. Abdel-Malek Z, Swope VB, Suzuki I, et al: Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci USA 92: 1789-1793, 1995.
39. Melmed S: Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7: 257-266, 2011.
40. Liddle GW, Island DP, Ney RL, Nicholson WE and Shimizu N: Nonpituitary neoplasms and cushing's syndrome: Ectopic 'adrenocorticotropin' produced by nonpituitary neoplasms as a cause of Cushing's syndrome. Arch Intern Med 111: 471-475, 1963.
41. Gewirtz G and Yalow RS: Ectopic ACTH production in carcinoma of the lung. J Clin Invest 53: 1022-1032, 1974.
42. Singer W, Kovacs K, Ryan N and Horvath E: Ectopic ACTH syndrome: clinicopathological correlations. J Clin Pathol 31: 591-598, 1978.
43. Halkerston ID: Cyclic AMP and adrenocortical function. Adv Cyclic Nucleotide Res 6: 99-136, 1975.